Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Politics

Can this European biotech challenge Eli Lilly in the booming weight-loss market?

admin by admin
October 11, 2024
in Politics
0
Can this European biotech challenge Eli Lilly in the booming weight-loss market?
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

GLP-1s have dominated discussions in 2024 among those exploring weight-loss treatments.

However, Zealand Pharma A/S (CPH: ZEAL), a Danish biotechnology firm, is already developing what it calls the “next generation” of anti-obesity therapy, aiming to outperform industry leaders like Eli Lilly and Novo Nordisk in the long term.

Zealand Pharma is testing Petrelintide, a long-acting amylin analog, for weight loss. Petrelintide boasts a better tolerability profile compared to existing treatments like Wegovy and Zepbound.

Shares of Zealand Pharma have more than doubled since the beginning of this year.

Petrelintide: a potential first-line weight-loss therapy

A Phase 1b trial has shown Petrelintide to be effective in reducing body weight by an average of 8.6%.

In a recent interview with CNBC, Zealand Pharma’s CEO, Adam Steensberg, said:

If we can develop a molecule for weight loss with a benign tolerability profile and demonstrate cardiovascular risk reduction, we have every reason to believe it could become a first-line therapy.

Zealand Pharma plans to proceed with a Phase 2b trial by the end of 2024.

Amylin analogs mimic a hormone that increases satiety and is naturally produced in the human body alongside insulin by the pancreas, a large gland located behind the stomach.

Despite a significant year-to-date rally, Zealand Pharma stock could climb further as it solidifies its place in a high-growth market, projected to be worth around $200 billion by the end of this decade.

However, at the time of writing, the stock does not pay a dividend.

Should you invest in Zealand Pharma stock in October?

While excitement around Petrelintide is growing, analysts at Deutsche Bank caution that much of the optimism may already be priced in.

With a market cap of approximately $9 billion, the stock may have limited upside in the near term.

Last week, Deutsche Bank initiated coverage of Zealand Pharma with a “hold” rating and a price target of DKK 815, indicating only a 4% potential increase from its current level.

Nonetheless, Zealand Pharma is showing strong growth. In the first half of 2024, the company generated DKK 49.2 million in revenue, more than double the DKK 24 million it reported for the same period in 2023.

The company also completed a $1.0 billion upsized equity offering in June, reflecting strong investor interest in its R&D and commercialization efforts. At that time, CEO Adam Steensberg stated:

“Backed by a solid financial position following the capital raise in June, we’re making significant investments in our differentiated obesity candidates to accelerate their development as we explore partnership opportunities.”

The post Can this European biotech challenge Eli Lilly in the booming weight-loss market? appeared first on Invezz

Previous Post

JPMorgan earnings beat by $0.38, revenue topped estimates

Next Post

October is historically a good month for crypto: could Dogizen benefit?

admin

admin

Next Post
October is historically a good month for crypto: could Dogizen benefit?

October is historically a good month for crypto: could Dogizen benefit?

Trending News

American Airlines surges after lifting Q4 profit guide

American Airlines surges after lifting Q4 profit guide

December 5, 2024
While farmers protest, UK’s Starmer says will defend budget ‘all day long’

While farmers protest, UK’s Starmer says will defend budget ‘all day long’

November 16, 2024
How billionaire Caltagirone could influence Italy’s banking M&A wave

How billionaire Caltagirone could influence Italy’s banking M&A wave

May 24, 2025
Subscribe to Insightful Word


    Recent News

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    June 26, 2025
    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    June 26, 2025
    S&P 500 nears record high as Wall Street opens higher amid tech momentum

    S&P 500 nears record high as Wall Street opens higher amid tech momentum

    June 26, 2025
    Galaxy Digital launches $175 million fund to back DeFi and stablecoin startups

    Galaxy Digital launches $175 million fund to back DeFi and stablecoin startups

    June 26, 2025

    Recent News

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    June 26, 2025
    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    June 26, 2025

    Latest News

    • S&P 500 nears record high despite headwinds: key drivers behind the surprise rally
    • Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high
    • S&P 500 nears record high as Wall Street opens higher amid tech momentum

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.